港股异动 | 拨康视云-B(02592)现涨超4% 附属将与美国FDA讨论CBT-004研发事项

Core Viewpoint - The stock of Bolekang Shiyun-B (02592) has increased by over 4%, currently trading at 8.58 HKD with a transaction volume of 11.82 million HKD, following the announcement of a significant milestone in the development of its candidate drug CBT-004 [1] Group 1 - Bolekang Shiyun has a wholly-owned subsidiary, Cloudbreak USA, registered in California, which is scheduled to hold a post-phase 2 clinical trial meeting with the U.S. Food and Drug Administration on December 10, 2025 [1] - The upcoming meeting is a crucial milestone in the development process of CBT-004, aimed at discussing the potential requirements for phase 3 clinical trial development and new drug application [1]